PubMed 21 Di Bonaventura G, Pompilio A, Picciani C, Nicoletti M,

PubMed 21. Di Bonaventura G, Pompilio A, Picciani C, Nicoletti M, Zappacosta R, Piccolomini R: Adhesion to and biofilm formation on IB3–1 bronchial cells by Stenotrophomonas maltophilia : implications in cystic fibrosis [abstract]. Clin Microbiol Infect 2008, 14:s178. 22. de Oliveira-Garcia D, Dall’Agnol M, Rosales M, Azzuz AC, Martinez MB, Girón JA: Characterization of flagella produced by clinical strains of Stenotrophomonas maltophilia . Emerg Infect Dis 2002, 8:918–923.PubMed 23. O’Sullivan BP, Freedman SD: Cystic fibrosis.

Lancet 2009, 373:1891–1904.PubMedCrossRef 24. Ryan RP, Monchy S, Cardinale M, Taghavi S, Crossman L, Avison MB, Berg G, Lelie D, Dow JM: The versatility and adaptation of bacteria from the genus Stenotrophomonas . #GDC-0449 cell line randurls[1|1|,|CHEM1|]# Nat Rev Microbiol 2009, 7:514–525.PubMedCrossRef 25. Graff GR, Burns IWP-2 solubility dmso JL: Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest 2002, 121:1754–1760.PubMedCrossRef 26. Goss CH, Otto K, Aitken ML, Rubenfeld GD: Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am J Respir

Crit Care Med 2002, 166:356–361.PubMedCrossRef 27. Nicodemo AC, Paez JI: Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis 2007, 26:229–237.PubMedCrossRef 28. Kirisits MJ, Parsek MR: Does Pseudomonas aeruginosa use intercellular signalling to build biofilm communities? Cell Microbiol 2006, 8:1841–1849.PubMedCrossRef 29. Ewig S, Soler N, Gonzalez J, Celis R, El-Ebiary M, Torres A: Evaluation of antimicrobial treatment in mechanically ventilated patients with severe chronic obstructive pulmonary disease exacerbations. Crit Care Med 2000, 28:692–697.PubMedCrossRef 30. Valdezate S, Vindel A, Maiz L, Baquero F, Escobar H, Cantón R: Persistence and variability of Stenotrophomonas maltophilia in

Phospholipase D1 cystic fibrosis patients, Madrid, 1991–1998. Emerg Infect Dis 2001, 7:113–122.PubMedCrossRef 31. Sampaio SC, Gomes TA, Pichon C, du Merle L, Guadagnini S, Abe CM, Sampaio JL, Le Bouguènec C: The flagella of an atypical enteropathogenic Escherichia coli are required for efficient interaction with and stimulation of IL-8 production by enterocytes in vitro. Infect Immun 2009,77(10):4406–13.PubMedCrossRef 32. Yonekura K, Maki-Yonekura S, Namba K: Growth mechanism of the bacterial flagellar filament. Res Microbiol 2002, 153:191–197.PubMedCrossRef 33. Stepanoviæ S, Vukoviæ D, Hola V, Di Bonaventura G, Djukiæ S, Cirkoviæ I, Ruzicka F: Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. APMIS 2007, 15:891–899.CrossRef 34. Pompilio A, Piccolomini R, Picciani C, D’Antonio D, Savini V, Di Bonaventura G: Factors associated with adherence to and biofilm formation on polystyrene by Stenotrophomonas maltophilia : the role of cell surface hydrophobicity and motility. FEMS Microbiol Lett 2008, 287:41–47.PubMedCrossRef 35.

Related posts:

  1. J Clin Microbiol 1982,15(5):873–878 PubMed 4 Harasawa R, Kanamot
  2. Periodontol 2006, 42:80–87 CrossRef 8 Zijnge V, Ammann T, Thurnh
  3. Emerg Infect Dis 2006,12(5):769–771 PubMed 23 Sahraoui N, Muller
  4. Nature 2002, 417:552–555 PubMedCrossRef

    18 Cole GT, Hala
  5. J Bacteriol 1996, 178:424–434 PubMed 66 Zeng X,
This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>